1. Austin A, Lietman T, Rose-Nussbaumer J. Update on the management of infectious keratitis. Ophthalmology 124, 1678-1689 (2017).
2. Hernandez, F., Huang, L., Olson, M. et al. Noninvasive imaging of Staphylococcus aureus infections with a nuclease-activated probe. Nat. Med. 20, 301-306 (2014).
3. Koskiniemi, S. & Virtanen, P. Selective killing of antibiotic-resistant bacteria from within. Nature, 570, 449–450 (2019).
4. Mourtada, R., Herce, H.D., Yin, D.J. et al. Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice. Nat. Biotechnol. 37, 1186–1197 (2019).
5. Bikard, D. et al. Exploiting CRISPR-Cas nucleases to produce sequencespecific antimicrobials. Nat. Biotechnol. 32, 1146–1150 (2014).
6. Citorik, R. J., Mimee, M. & Lu, T. K. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 32, 1141–1145 (2014).
7. Rodriguez-Pagan, I., Novick, R. P., Ross, H. F., Jiang, D. & Ram, G. Conversion of staphylococcal pathogenicity islands to CRISPR-carrying antibacterial agents that cure infections in mice. Nat. Biotechnol. 36, 971–976 (2018).
8. López-Igual, R., Bernal-Bayard, J., Rodríguez-Patón, A. et al. Engineered toxin–intein antimicrobials can selectively target and kill antibiotic-resistant bacteria in mixed populations. Nat. Biotechnol. 37, 755–760 (2019).
9. Chikindas, M. L., Weeks, R., Drider, D., Chistyakov, V. A. & Dicks, L. M. Functions and emerging applications of bacteriocins. Curr. Opin. Biotech. 49, 23–28 (2018).
10. Good L, Awasthi S K, Dryselius R, et al. Bactericidal antisense effects of peptide-PNA conjugates. Nat. Biotechnol. 19, 360-364 (2001).
11. Delihas, N., Rokita, S. & Zheng, P. Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design. Nat. Biotechnol. 15, 751-753 (1997).
12. Harth, G., Zamecnik, P. C., Tabatadze, D., et al. Hairpin extensions enhance the efficacy of mycolyl transferase-specific antisense oligonucleotides targeting Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U S A. 104, 7199 (2007).
13. Harth, G., Zamecnik, P. C. & Tang, J. Y. Treatment of mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-l-glutamate/glutamine cell wall structure, and bacterial replication. Proc. Natl. Acad. Sci. U S A. 97, 418-423 (2000).
14. Wesolowski, D. et al. Basicpeptide-morpholino oligomer conjugate that is very effective in killing bacteria by gene-specific and nonspecific modes. Proc. Natl. Acad. Sci. U S A. 108, 16582-16587 (2011).
15. Good, L. & Nielsen, P. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat. Biotechnol. 16, 355-358 (1998).
16. Pernitzsch, S. R., Alzheimer, M., Bremer, B. U. et al. Small RNA mediated gradual control of lipopolysaccharide biosynthesis affects antibiotic resistance in Helicobacter pylori. Nat. Commun. 12, 4433 (2021).
17. Hegarty, J. P. & Stewart, D. B. Advances in therapeutic bacterial antisense biotechnology. Appl. Microbiol. Biotechnol. 102, 1055-1065 (2018).
18. Bessa, L. J., Ferreira, M. & Gameiro, P. Evaluation of membrane fluidity of multidrug-resistant isolates of Escherichia coli and Staphylococcus aureus in presence and absence of antibiotics. J. Photochem. Photobiol. B. 181, 150-156 (2018).
19. Zhang, Y., Ma, W., Ying, Z., et al. Inhibiting methicillin-resistant Staphylococcus aureus by tetrahedral DNA nanostructure-enabled antisense peptide nucleic acid delivery. Nano Lett. 18, 5652-5659 (2018).
20. van Haasteren, J., Li, J., Scheideler, O.J. et al. The delivery challenge: fulfilling the promise of therapeutic genome editing. Nat. Biotechnol. 38, 845–855 (2020).
21. Crooke, S., Wang, S., Vickers, T. et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat. Biotechnol. 35, 230–237 (2017).
22. Ho, H., Miu, A., Alexander, M.K. et al. Structural basis for dual-mode inhibition of the ABC transporter MsbA. Nature 557, 196–201 (2018).
23. Chen, S., Oldham, M., Davidson, A. et al. Carbon catabolite repression of the maltose transporter revealed by X-ray crystallography. Nature 499, 364–368 (2013).
24. Oldham, M. L., Khare, D., Quiocho, F. A., Davidson, A. L. & Chen, J. Crystal structure of a catalytic intermediate of the maltose transporter. Nature 450, 515–521 (2007)
25. Oldham, M. L. & Chen, J. Crystal structure of the maltose transporter in a pretranslocation intermediate state. Science 332, 1202–1205 (2011).
26. Gerber, S., Comellas-Bigler, M., Goetz, B. A. & Locher, K. P. Structural basis of trans-inhibition in a molybdate/tungstate ABC transporter. Science 321, 246–250 (2008).
27. Ning, X., Lee, S., Wang, Z. et al. Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity. Nat. Mater. 10, 602-607 (2011).
28. Zlitni, A., Gowrishankar, G., Steinberg, I. et al. Maltotriose-based probes for fluorescence and photoacoustic imaging of bacterial infections. Nat. Commun. 11, 1250 (2020).
29. Tang. J., Chu, B., Wang, J., et al. Multifunctional nanoagents for ultrasensitive imaging and photoactive killing of Gram-negative and Gram-positive bacteria. Nat. Commun. 10, 1-14 (2019).
30. Bordignon, E., Grote, M. & Schneider, E. The maltose ATP-binding cassette transporter in the 21st century-towards a structural dynamic perspective on its mode of action. Mol. Microbiol. 77, 1354-1366 (2010).
31. Klebba, P. E. Mechanism of maltodextrin transport through LamB. Res. Microbiol. 153, 417-424 (2002).
32. Charbit, A. Maltodextrin transport through LamB. Front. Biosci. 8, s265-274 (2003).
33. Dippel, R., Boos, W. The maltodextrin system of Escherichia coli: metabolism and transport. J. Bacteriol. 187, 8322-8331 (2005).
34. Schonert, S., Seitz, S., Krafft, H. et al. Maltose and maltodextrin utilization by Bacillus subtilis. J. Bacteriol. 188, 3911-3922 (2006).
35. Prince, J. P., Bolla, J. R., Fisher, G. L. M., et al. Acyl carrier protein is essential for MukBEF action in Escherichia coli chromosome organization-segregation. Nat. Commun. 12, 6721 (2021).
36. Chen, A., Re, R. N. & Burkart, M. D. Type II fatty acid and polyketide synthases: deciphering protein–protein and protein-substrate interactions. Nat. Prod. Rep. 35, 1029-1045 (2018).
37. Li, G. W., Burkhardt, D., Gross, C., et al. Quantifying absolute protein synthesis rates reveals principles underlying allocation of cellular resources. Cell 157, 624–635 (2014).
38. Dryselius, R., Nekhotiaeva, N., Nielsen, P. E., et al. Antibiotic-free bacterial strain selection using antisense peptide nucleic acid. Biotechniques 35, 1060-1064 (2003).
39. Nekhotiaeva, N., Awasthi, S. K., Nielsen, P. E, et al. Inhibition of Staphylococcus aureus gene expression and growth using antisense peptide nucleic acids. Mol. Ther. 10, 652-659 (2004).
40. Järver, P., Coursindel, T., Andaloussi, S. E., et al. Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA. Mol. Ther. Nucleic Acids. 1, e27 (2012).
41. Patenge, N., Pappesch, R., Krawack, F., et al. Inhibition of growth and gene expression by PNA-peptide conjugates in Streptococcus pyogenes. Mol. Ther. Nucleic Acids. 2, e132 (2013).
42. Leary, S. C. et al. Chronic treatment with azide in situ leads to an irreversible loss of cytochrome C oxidase activity via holoenzyme dissociation. J. Biol. Chem. 277, 11321–11328 (2002).
43. Kim, Y. C., Shin, M. D., Hackett, S. F. et al. Gelling hypotonic polymer solution for extended topical drug delivery to the eye. Nat. Biomed. Eng. 4, 1053-1062 (2020).
44. Weng, Y. H., Ma, X. W., Che, J. et al. Nanomicelle-assisted targeted ocular delivery with enhanced antiinflammatory efficacy in vivo. Adv. Sci. 5, 1700455 (2018).
45. Seah, I., Loh, X. J. & Su, X. A topical gel for extended ocular drug release. Nat. Biomed. Eng. 4, 1024-1025 (2020).
46. Ch’ng, J. H., Chong, K. K. L., Lam, L. N. et al. Biofilm-associated infection by enterococci. Nat. Rev. Microbiol. 17, 82–94 (2019).
47. Bourdeau, R., Lee-Gosselin, A., Lakshmanan, A. et al. Acoustic reporter genes for noninvasive imaging of microorganisms in mammalian hosts. Nature 553, 86–90 (2018).